Skip to main content
Premium Trial:

Request an Annual Quote

Miltenyi Buys Cell Sorting Firm Owl Biomedical

NEW YORK (GenomeWeb News) – German firm Miltenyi Biotec today announced it has completed its acquisition of microchip cell sorting company Owl Biomedical for an undisclosed amount.

Based in Santa Barbara, Calif., Owl was founded in 2011. Its first product, called the Nanosorter, uses a closed fluid path cartridge for "plug and play" cell sorting. The technology can process samples efficiently in a clean environment isolated from the laboratory setting, Miltenyi said.

"This acquisition combines Owl's innovative microchip-based, high speed cell sorting technology and intellectual property with Miltenyi Biotec's strength in commercial design, manufacturing and marketing," John Foster, president of Owl, said in a statement. "This combination provides assurance that our technology will get to market in a timely manner with the highest quality engineering."

Based in Bergisch Gladbach, Germany, Miltenyi provides products and services for biomedical research.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.